SLCTR/2013/024已完成未知
Randomized, double blind, controlled, comparative clinical trial on efficacy and safety of intralesional 10% and 15% hypertonic saline vs sodium stiboglucate in cutaneous leishmaniasis
Teaching Hospital Anuradhapura0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All consenting patients presenting to the Skin Clinic, Teaching Hospital, Anuradhapura with a clinical diagnosis of cutaneous leishmaniasis, confirmed by slit-skin smear will be included.
排除标准
- •1.Pregnancy
- •2.Breast feeding
- •3.Known renal impairment
- •4.Known liver impairment
- •5.Congestive cardiac failure
研究者
相似试验
进行中（未招募）
不适用
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseEUCTR2008-006957-42-LVDr. Falk Pharma GmbH400
进行中（未招募）
不适用
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 14.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2008-006957-42-LTDr. Falk Pharma GmbH500
进行中（未招募）
不适用
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 12.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeMedDRA version: 12.0Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-006957-42-HUDr. Falk Pharma GmbH400
进行中（未招募）
不适用
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 12.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeMedDRA version: 12.0Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-006957-42-SKDr. Falk Pharma GmbH400
进行中（未招募）
不适用
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 12.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeMedDRA version: 12.0Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-006957-42-CZDr. Falk Pharma GmbH400